Literature DB >> 21333235

Factors influencing the response of interferon therapy in chronic hepatitis C patients.

Waquar Uddin Ahmed1, Ambreen Arif, Huma Qureshi, Syed Ejaz Alam, Raheel Ather, Shamoona Fariha, Javeria Waquar.   

Abstract

OBJECTIVE: To determine factors influencing response of interferon therapy in chronic hepatitis C patients. STUDY
DESIGN: Descriptive, analytical study. PLACE AND DURATION OF STUDY: Pakistan Medical Research Centre, Jinnah Postgraduate Medical Centre, Karachi, from January 1998 to December 2009.
METHODOLOGY: Patients of chronic hepatitis C treated with conventional interferon were retrospectively analyzed. End treatment response at 6 months for genotype 2 and 3 and one-year for genotype 1 and 4 was assessed. Sustained virological response was checked after 6 months of cessation of therapy. Non-compliant and incomplete follow-up cases were excluded. Factors influencing the response to therapy were analyzed by univariate and multivariate logistic regression analysis.
RESULTS: A total of 932 cases received interferon therapy 103 were lost to follow-up and were excluded. Treatment was completed in 829 cases end treatment response was 74% (615 out of 829 cases). Six months post-treatment follow-up was available in 492 cases. Sustained virological response was seen in 63% (308 out of 492 cases). Univariate logistic regression analysis showed significantly better response in patients with <40 years of age, body weight>70 kg, normal platelet count, serum albumin>4.0 grams, non diabetic patients and those with a normal alanine aminotransferase (ALT) at 1st month of therapy. Multiple logistic regression analysis showed that only age<40 years was significantly important for sustained virological response.
CONCLUSION: For conventional interferon therapy, age<40 years is the best predictor for sustained virological response, however, better response can be achieved in patients with <70 kg weight, normal platelet count, serum albumin>4.0 grams, non-diabetics and patients having normal ALT at 1st month of therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21333235     DOI: 02.2011/JCPSP.6973

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  4 in total

Review 1.  Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Nathan Ford; Catherine Kirby; Kasha Singh; Edward J Mills; Graham Cooke; Adeeba Kamarulzaman; Philipp duCros
Journal:  Bull World Health Organ       Date:  2012-02-03       Impact factor: 9.408

Review 2.  A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.

Authors:  Muhammad Ali; Samia Afzal; Asad Zia; Ahmed Hassan; Ali Talha Khalil; Muhammad Ovais; Zabta Khan Shinwari; Muhammad Idrees
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

3.  Presence of HCV RNA in peripheral blood mononuclear cells may predict patients response to interferon and ribavirin therapy.

Authors:  Nasib Zaman; Muhammad Javaid Asad; Abida Raza; Ghazala Kaukab Raja; Shamim Akhter; Majid Mahmood; Raja Tahir Mahmood
Journal:  Ann Saudi Med       Date:  2014 Sep-Oct       Impact factor: 1.526

4.  End treatment response and sustained viral response in hepatitis C virus genotype 3 among Pakistani population.

Authors:  Muhammad Amir; Attiya Sabeen Rahman; Qaiser Jamal; Muhammad Asadullah Siddiqui
Journal:  Ann Saudi Med       Date:  2013 Nov-Dec       Impact factor: 1.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.